IndexCopernicus™ Authors Information
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
John J V McMurray, James B Young, Mark E Dunlap, Christopher B Granger, James Hainer, Eric L Michelson, Steven Earle, Bertil Olofsson, Jan Ostergren, Salim Yusuf, Karl Swedberg, Marc A Pfeffer
Am Heart J 2006; 151(5):985-991
ICID: 823957
IC™ Value: 2.00
Author's profile available for:
  • Mark E Dunlap - click here